Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Background: Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. Methods: A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion. Results: Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available. Conclusions: Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare cases of severe or critical disease, this guidance offers an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288 · cited 1×
“However, the azithromycin-treated patients had significantly higher viral cycle thresholds at baseline, suggesting that they had a lower baseline viral load and were more likely to experience viral clearance, independent of azithromycin use (76).”
BackgroundRetractedClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 1×
“Based on observational data in adults, individuals with diabetes mellitus appear to be at elevated risk for several complications of COVID-19, including progression to severe disease, development of ARDS, and in-hospital death (23,25,48).”
BackgroundWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148 · cited 1×
“Adult data suggest that, in addition to older age, presence of cardiovascular disease, chronic respiratory disease, hypertension, or cerebrovascular disease is associated with COVID-19-related morbidity and mortality (25, (33) (34) (35) .”
BackgroundLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249 · cited 1×
“Based on observational data in adults, individuals with diabetes mellitus appear to be at elevated risk for several complications of COVID-19, including progression to severe disease, development of ARDS, and in-hospital death (23,25,48).”
BackgroundRemdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958 · cited 2×
“Data from SARS-CoV-2-infected Vero E6 cells demonstrate the in vitro efficacy of both chloroquine and hydroxychloroquine with EC50 concentrations potentially achievable with available dosing regimens, though data are conflicting as to which of the two agents is more potent against SARSCoV-2 (55,67,68).”
BackgroundFirst case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030 · cited 1×
“Published data describing use of remdesivir for COVID-19 include a case report and case series (60) (61) (62) .”
MethodA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187 · cited 2×
“Further, a randomized trial demonstrated no difference in time to clinical improvement or virologic outcomes in severely ill adults with COVID-19 treated with lopinavir-ritonavir as compared with usual care (92).”
BackgroundCancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384 · cited 1×
“Reports from China demonstrate that adults with COVID-19 and malignancies have increased mortality compared with patients of similar ages (22,23).”
BackgroundYang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.017 · Cited by 4,206
Epidemiology of COVID-19 Among Children in China
Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., & Tong, S. (2020) · Pediatrics · doi:10.1542/peds.2020-0702 · Cited by 4,090
Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis
Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., Wang, T., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00547-2020 · Cited by 3,680 · cited 1×
“In a nationwide Chinese cohort, malignancy was an independent risk factor for mortality after adjusting for age and smoking status (24) .”
BackgroundWang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
(2020) · PubMed · doi:10.3760/cma.j.issn.0254-6450.2020.02.003 · Cited by 3,323
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,054
Self-citation2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737 · cited 1×
“Transaminase elevations were identified in 23% (62).”
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662 · cited 3×
“Data from SARS-CoV-2-infected Vero E6 cells demonstrate the in vitro efficacy of both chloroquine and hydroxychloroquine with EC50 concentrations potentially achievable with available dosing regimens, though data are conflicting as to which of the two agents is more potent against SARSCoV-2 (55,67,68).”
BackgroundMethodMultisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,643
Self-citationGao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590 · cited 2×
“Until late March 2020, supportive human data were limited to announcement of "more than 100 patients [demonstrating] that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the di…”
BackgroundVerdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., Bonanomi, E., & D'Antiga, L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31103-x · Cited by 2,380
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S., Boundy, E., Bowen, V., Chow, N., Cohn, A., Dowling, N., Ellington, S., Gierke, R., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,277
The Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,246
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070 · cited 1×
“Data from SARS-CoV-2-infected Vero E6 cells demonstrate the in vitro efficacy of both chloroquine and hydroxychloroquine with EC50 concentrations potentially achievable with available dosing regimens, though data are conflicting as to which of the two agents is more potent against SARSCoV-2 (55,67,68).”
BackgroundEpidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., Ng, O.-T., Marimuthu, K., Ang, L. W., Mak, T. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3204 · Cited by 2,059 · cited 2×
“Several additional adult case series report favorable clinical outcomes among lopinavirritonavir-treated patients, but illness severity, concomitant therapies, and the lack of comparator groups preclude any statement of efficacy (111) (112) (113) .”
BackgroundWhittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C. E., Shah, P., Ramnarayan, P., Fraisse, A., Miller, O., Davies, P., et al. (2020) · JAMA · doi:10.1001/jama.2020.10369 · Cited by 1,994
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738 · cited 1×
“Lopinavirritonavir and IFN-β given one day after infection improved pulmonary function but failed to reduce viral replication, lung hemorrhaging, or viral titers (56) .”
BackgroundSelf-citationClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654 · cited 1×
“The contribution to critical COVID-19 of direct viral infection versus a deleterious immune response is not yet well understood (15).”
BackgroundRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645 · cited 1×
“Further, the small number of exposed patients limited the ability to adjust for many confounders, aside from admission LDH (105) .”
BackgroundObservational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012410 · Cited by 1,625
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,609
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605 · cited 3×
“There was a single SAE potentially attributed to remdesivir, which was infusion-related hypotension in a 41-year-old man (50).”
BackgroundInfluentialBroad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571 · cited 8×
“Administration of potentially active antivirals without confirmation of SARS-CoV-2 infection poses a significant risk of exposing patients to unnecessary harms from these medications without the possibility of benefit.”
BackgroundResultInfluentialSelf-citationCoronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Wang, Y., Wang, Y., Chen, Y., & Qin, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25748 · Cited by 1,531 · cited 1×
“Adult data suggest that, in addition to older age, presence of cardiovascular disease, chronic respiratory disease, hypertension, or cerebrovascular disease is associated with COVID-19-related morbidity and mortality (25, (33) (34) (35) .”
BackgroundCoronavirus Disease 2019 in Children — United States, February 12–April 2, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S., Gierke, R., Hughes, M., McNamara, L. A., Pilishvili, T., & Skoff, T. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6914e4 · Cited by 1,525
Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., Jia, P., Guan, H. Q., Peng, L., Chen, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.296 · Cited by 1,498
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Self-citationXu, Y., Li, X., Zhu, B., Liang, H., Fang, C., Gong, Y., Guo, Q., Sun, X., Zhao, D., Shen, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0817-4 · Cited by 1,415 · cited 1×
“Multiple other reports also have described children aged 1–11 months with only mildly symptomatic infection who improved without intervention [17, 18].”
BackgroundRemdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015301 · Cited by 1,362
Multisystem Inflammatory Syndrome in Children in New York State
Dufort, E. M., Koumans, E. H., Chow, E. J., Rosenthal, E. M., Muse, A., Rowlands, J., Barranco, M. A., Maxted, A. M., Rosenberg, E. S., Easton, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021756 · Cited by 1,350
Children With Medical Complexity: An Emerging Population for Clinical and Research Initiatives
Cohen, E., Kuo, D. Z., Agrawal, R., Berry, J. G., Bhagat, S. K. M., Simon, T. D., & Srivastava, R. (2011) · Pediatrics · doi:10.1542/peds.2010-0910 · Cited by 1,340
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318
Qiu, H., Wu, J., Hong, L., Luo, Y., Song, Q., & Chen, D. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30198-5 · Cited by 1,283 · cited 1×
“All patients recovered, and no comparisons were made between treated and untreated patients (110) .”
BackgroundObesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission
Lighter, J., Phillips, M., Hochman, S., Sterling, S., Johnson, D., Francois, F., & Stachel, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa415 · Cited by 1,225
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
Götzinger, F., Santiago-García, B., Noguera-Julián, A., Lanaspa, M., Lancella, L., Calò Carducci, F. I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., et al. (2020) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30177-2 · Cited by 1,219
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160 · cited 1×
“Optimal treatment duration is similarly uncertain, with five days being most commonly used in published reports, but anywhere from 3-14 days reported (51, 71, (82) (83) (84) (85) .”
Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., et al. (2020) · JAMA · doi:10.1001/jama.2020.8630 · Cited by 1,156
Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., Fourgeaud, J., Angoulvant, F., Debray, A., Basmaci, R., Salvador, E., Biscardi, S., et al. (2020) · BMJ · doi:10.1136/bmj.m2094 · Cited by 1,144
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
Zimmermann, P., & Curtis, N. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,077
Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults
Xia, W., Shao, J., Guo, Y., Peng, X., Li, Z., & Hu, D. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.24718 · Cited by 1,057
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C.-C., Edwards, K. M., Gandhi, R., Muller, W. J., O’Horo, J. C., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa478 · Cited by 1,033
Coronavirus disease 2019 (COVID-19) in Italy
Livingston, E., & Bucher, K. (2020) · JAMA · doi:10.1001/jama.2020.4344 · Cited by 1,010 · cited 1×
“Similarly, early data from Italy report no mortality in the 0- to 19-year age group (19).”
BackgroundShekerdemian, L. S., Mahmood, N. R., Wolfe, K. K., Riggs, B. J., Ross, C. E., McKiernan, C. A., Heidemann, S. M., Kleinman, L. C., Sen, A. I., Hall, M. W., et al. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.1948 · Cited by 985
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Jiehao, C., Jin, X., Daojiong, L., Zhi, Y., Lei, X., Zhenghai, Q., Yuehua, Z., Hua, Z., Ran, J., Pengcheng, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa198 · Cited by 921 · cited 1×
“Currently available data are insufficient to establish whether immunocompromised children are at greater risk of severe COVID-19 than healthy children or those with other comorbidities (6,20).”
Backgroundde Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887 · cited 7×
“Administration of potentially active antivirals without confirmation of SARS-CoV-2 infection poses a significant risk of exposing patients to unnecessary harms from these medications without the possibility of benefit.”
ResultInfluential2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary
Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1028 · Cited by 879
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.013056 · Cited by 850
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020
Godfred-Cato, S., Bryant, B., Leung, J., Oster, M. E., Conklin, L., Abrams, J., Roguski, K., Wallace, B., Prezzato, E., Koumans, E. H., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e2 · Cited by 769
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101663 · Cited by 765 · cited 2×
“Since, limited primary data from small randomized controlled trials and observational studies have become available with conflicting results (72) (73) (74) (75) (76) (77) .”
BackgroundDetection of Covid-19 in Children in Early January 2020 in Wuhan, China
Liu, W., Zhang, Q., Chen, J., Xiang, R., Song, H., Shu, S., Chen, L., Liang, L., Zhou, J., You, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2003717 · Cited by 751
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 749
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy
Marmor, M. F., Kellner, U., Lai, T. Y. Y., Lyons, J. S., & Mieler, W. F. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.11.017 · Cited by 710
Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China
Cai, Q., Chen, F., Wang, T., Luo, F., Liu, X., Wu, Q., He, Q., Wang, Z., Liu, Y., Liu, L., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0576 · Cited by 706
Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Zimetbaum, P. J., & Gold, H. S. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1834 · Cited by 698
Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.110531 · Cited by 688 · cited 1×
“However, there is evidence to support more severe outcomes from other respiratory viral infections, such as influenza (36, 37) , parainfluenza (38) , RSV (39) (40) (41) (42) , and non-COVID-19 coronaviruses (26,43), in children with chronic cardiac and pulmonary conditions.”
BackgroundNovel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China
Wei, M., Yuan, J., Liu, Y., Fu, T., Yu, X., & Zhang, Z.-J. (2020) · JAMA · doi:10.1001/jama.2020.2131 · Cited by 673 · cited 1×
“Multiple other reports also have described children 1 to 11 months of age with only mildly symptomatic infection who improved without intervention (17,18).”
Background[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 664
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020) · Med · doi:10.1016/j.medj.2020.06.001 · Cited by 656
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643 · cited 1×
“Pharmacokinetic studies of remdesivir have been performed, but primary data have not been published (59).”
BackgroundLim, J., Jeon, S., Shin, H.-Y., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K.-W., Kang, Y. M., Lee, B., & Park, S.-J. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e79 · Cited by 636
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Social Science Research Network
(2007) · Choice Reviews Online · doi:10.5860/choice.45-0058 · Cited by 596
Stockman, J. A. (2008) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)70503-7 · Cited by 595
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Kuo, D. Z. (2011) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2011.172 · Cited by 548
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., McKinnon, J. E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.099 · Cited by 546
Wang, Z., Chen, X., Lu, Y., Chen, F., & Zhang, W. (2020) · BioScience Trends · doi:10.5582/bst.2020.01030 · Cited by 544 · cited 1×
“Several additional adult case series report favorable clinical outcomes among lopinavirritonavir-treated patients, but illness severity, concomitant therapies, and the lack of comparator groups preclude any statement of efficacy (111) (112) (113) .”
BackgroundIn vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lu, H. T., Fan, K. W., Cheng, V. C. C., Tsui, W. H. W., Hung, I. F. N., & Lee, T. S. W. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.03.003 · Cited by 534
Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China
Eastin, C., & Eastin, T. (2020) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2020.04.006 · Cited by 532 · cited 2×
“published by Dong and colleagues demonstrated that among 2,143 confirmed and suspected pediatric cases in China, >90% had asymptomatic, mild, or moderate infections, where moderate disease was defined as pneumonia with fever, cough, and possible abnormalities on chest imaging but no hypoxemia or shortness of breath (1…”
BackgroundKim, L., Whitaker, M., O’Halloran, A., Kambhampati, A., Chai, S. J., Reingold, A., Armistead, I., Kawasaki, B., Meek, J., Yousey-Hindes, K., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e3 · Cited by 513
Zachariah, P., Johnson, C. L., Halabi, K. C., Ahn, D., Sen, A. I., Fischer, A., Banker, S. L., Giordano, M., Manice, C. S., Diamond, R., et al. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.2430 · Cited by 511
Self-citationKalil, A. C. (2020) · JAMA · doi:10.1001/jama.2020.4742 · Cited by 497 · cited 1×
“Third, the optimal pathway for introducing novel therapies, even in a pandemic, is to do so as part of well-designed, randomized controlled trials (3).”
BackgroundChan, K., Lai, S. T., Chu, C., Tsui, E. L. H., Tam, C. Y., Wong, M. M.-L., Tse, M. W., Que, T. L., Peiris, M. J. S., Sung, J. J. �., et al. (2003) · PubMed · Cited by 478
Ogden, C. L., Carroll, M. D., Fakhouri, T. H., Hales, C. M., Fryar, C. D., Li, X., & Freedman, D. S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6706a3 · Cited by 475
Al-Bari, M. A. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv018 · Cited by 467
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444 · cited 1×
“, ribavirin) are ineffective against coronaviruses due to the proofreading capability of a unique 3’-to-5’ exoribonuclease and resultant high-fidelity viral replication, remdesivir appears to maintain activity despite this exoribonuclease (52,53).”
BackgroundSelf-citationAssociation of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019
Kalligeros, M., Shehadeh, F., Mylona, E. K., Benitez, G., Beckwith, C. G., Chan, P. A., & Mylonakis, E. (2020) · Obesity · doi:10.1002/oby.22859 · Cited by 442
Obesity could shift severe COVID-19 disease to younger ages
Kass, D. A., Duggal, P., & Cingolani, O. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31024-2 · Cited by 435
Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China
Shanghai (2020) · Cited by 433
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Chorin, E., Dai, M., Shulman, E., Wadhwani, L., Bar-Cohen, R., Barbhaiya, C., Aizer, A., Holmes, D., Bernstein, S., Spinelli, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0888-2 · Cited by 417
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
COVID-19 in a Long-Term Care Facility — King County, Washington, February 27–March 9, 2020
McMichael, T. M., Clark, S., Pogosjans, S., Kay, M., Lewis, J., Baer, A., Kawakami, V., Lukoff, M. D., Ferro, J., Brostrom-Smith, C., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e1 · Cited by 382
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE)
Conhecimento, R. D. I. E. (2020) · Cited by 377
DeBiasi, R. L., Song, X., Delaney, M., Bell, M., Smith, K., Pershad, J., Ansusinha, E., Hahn, A., Hamdy, R., Harik, N., et al. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.007 · Cited by 357
Chao, J. Y., Derespina, K. R., Herold, B. C., Goldman, D. L., Aldrich, M., Weingarten, J., Ushay, H. M., Cabana, M. D., & Medar, S. S. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.006 · Cited by 336
Self-citationHIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., Doerr, H. W., Hunsmann, G., Otaka, A., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.083 · Cited by 306
Chorin, E., Wadhwani, L., Magnani, S., Dai, M., Shulman, E., Nadeau-Routhier, C., Knotts, R., Bar-Cohen, R., Kogan, E., Barbhaiya, C., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.05.014 · Cited by 295
Verhulst, S. L., Schrauwen, N., Haentjens, D., Suys, B., Rooman, R. P., Van Gaal, L., De Backer, W. A., & Desager, K. N. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.101089 · Cited by 273 · cited 1×
“19 patients at higher risk for poor respiratory outcomes due to impaired lung mechanics (47).”
BackgroundBioavailability of hydroxychloroquine tablets in healthy volunteers.
Tett, S., Cutler, D., Day, R., & Brown, K. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03439.x · Cited by 269 · cited 1×
“Relevant PK properties of the drug to consider when making dosing and duration determinations include a large volume of distribution and a long terminal half-life of up to 40 days (80).”
BackgroundHuang, R., Zhu, L., Xue, L., Liu, L., Yan, X., Wang, J., Zhang, B., Xu, T., Ji, F., Zhao, Y., et al. (2020) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0008280 · Cited by 259
Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., Alser, O., Alshammari, T. M., Biedermann, P., Banda, J. M., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30276-9 · Cited by 258
Childhood Multisystem Inflammatory Syndrome — A New Challenge in the Pandemic
Levin, M. (2020) · New England Journal of Medicine · doi:10.1056/nejme2023158 · Cited by 218
Barnard, D. L., Day, C. W., Bailey, K., Heiner, M., Montgomery, R., Lauridsen, L., Chan, P. K., & Sidwell, R. W. (2006) · Antiviral Chemistry and Chemotherapy · doi:10.1177/095632020601700505 · Cited by 210
COVID-19 in Children With Cancer in New York City
Boulad, F., Kamboj, M., Bouvier, N., Mauguen, A., & Kung, A. L. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2028 · Cited by 203
Hrusak, O., Kalina, T., Wolf, J., Balduzzi, A., Provenzi, M., Rizzari, C., Rives, S., del Pozo Carlavilla, M., Alonso, M. E. V., Domínguez-Pinilla, N., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.021 · Cited by 187
Self-citationMolecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors
Nukoolkarn, V., Lee, V. S., Malaisree, M., Aruksakulwong, O., & Hannongbua, S. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.07.030 · Cited by 176
Ogimi, C., Englund, J. A., Bradford, M. C., Qin, X., Boeckh, M., & Waghmare, A. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix093 · Cited by 171 · cited 2×
“However, there is evidence to support more severe outcomes from other respiratory viral infections, such as influenza (36,37), parainfluenza (38), RSV (39–42), and non-COVID-19 coronaviruses (26,43), in children with chronic cardiac and pulmonary conditions.”
BackgroundSelf-citationParri, N., Magistà, A. M., Marchetti, F., Cantoni, B. M., Arrighini, A., Romanengo, M., Felici, E., Urbino, A., Dalt, L. D., Verdoni, L., et al. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-020-03683-8 · Cited by 167
Kim, Y., Guthrie, K. A., Waghmare, A., Walsh, E. E., Falsey, A. R., Kuypers, J. M., Cent, A., Englund, J. A., & Boeckh, M. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit832 · Cited by 156
Self-citationParadoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection
Roques, P., Thiberville, S.-D., Dupuis-Maguiraga, L., Lum, F.-M., Labadie, K., Martinon, F., Gras, G., Lebon, P., Ng, L. F. P., De Lamballerie, X., et al. (2018) · Viruses · doi:10.3390/v10050268 · Cited by 152
Welliver, C., Checchia, P. A., Bauman, J. H., Fernandes, A. W., Mahadevia, P. J., & Hall, C. B. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.505126 · Cited by 143 · cited 1×
“However, there is evidence to support more severe outcomes from other respiratory viral infections, such as influenza (36, 37) , parainfluenza (38) , RSV (39) (40) (41) (42) , and non-COVID-19 coronaviruses (26,43), in children with chronic cardiac and pulmonary conditions.”
BackgroundCOVID-19 infection in children and adolescents with cancer in Madrid
de Rojas, T., Pérez‐Martínez, A., Cela, E., Baragaño, M., Galán, V., Mata, C., Peretó, A., & Madero, L. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28397 · Cited by 140
Waghmare, A., Campbell, A. P., Xie, H., Seo, S., Kuypers, J. M., Leisenring, W. M., Jerome, K. R., Englund, J. A., & Boeckh, M. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit639 · Cited by 134
Self-citationSeo, S., Xie, H., Campbell, A. P., Kuypers, J. M., Leisenring, W. M., Englund, J. A., & Boeckh, M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu134 · Cited by 130 · cited 1×
“Similar risk factors also predict poor outcomes in parainfluenza virus infection (31,32).”
BackgroundAlsaied, T., Aboulhosn, J., Cotts, T. B., Daniels, C. J., Etheridge, S. P., Feltes, T. F., Gurvitz, M. Z., Lewin, M., Oster, M. E., & Saidi, A. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017224 · Cited by 129
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
Chen, J., Xia, L., Liu, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa241 · Cited by 124
First 12 patients with coronavirus disease 2019 (COVID-19) in the United States
The COVID-19 Investigation Team, Kujawski, S. A., Wong, K. K., Collins, J. P., Epstein, L., Killerby, M. E., Midgley, C. M., Abedi, G. R., Ahmed, N. S., Almendares, O., et al. (2020) · medRxiv · doi:10.1101/2020.03.09.20032896 · Cited by 119 · cited 2×
“All recovered, but all developed transaminase elevations (61) .”
BackgroundMethodDerespina, K. R., Kaushik, S., Plichta, A. M., Conway, E. E., Bercow, A., Choi, J., Eisenberg, R. E., Gillen, J. K., Sen, A. I., Hennigan, C. M., et al. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.07.039 · Cited by 118
Bisogno, G., Provenzi, M., Zama, D., Tondo, A., Meazza, C., Colombini, A., Galaverna, F., Compagno, F., Carraro, F., Santis, R. D., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa088 · Cited by 101
Zhang, X. W., & Yap, Y. L. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.03.035 · Cited by 98
COVID-19 Infection in Iranian Children: A Case Series of 9 Patients
Rahimzadeh, G., Noghabi, M. E., Elyaderani, F. K., Navaeifar, M. R., Enayati, A., Anari, A. M., Hujati, M., Rezai, S., & Rezai, M. S. (2020) · Journal of Pediatrics Review · doi:10.32598/jpr.8.2.139 · Cited by 93 · cited 1×
“Further, while the evidence base evolves almost daily, the data supporting candidate medications for COVID-19 are sparse, based primarily on in vitro studies, animal models, and small clinical studies focused on adults, with only sporadic case series describing antiviral use in children (2) (3) (4) (5) .”
BackgroundOtto, W. R., Geoghegan, S., Posch, L. C., Bell, L. M., Coffin, S. E., Sammons, J. S., Harris, R. M., John, A. R. O., Luan, X., & Gerber, J. S. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa074 · Cited by 82
The Burden of Influenza Hospitalizations in Infants From 2003 to 2012, United States
Chaves, S. S., Pérez, A., Farley, M. M., Miller, L. A., Schaffner, W., Lindegren, M. L., Sharangpani, R., Meek, J. I., Yousey-Hindes, K. M., Thomas, A. R., et al. (2014) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000321 · Cited by 76
Updated recommendations on the use of hydroxychloroquine in dermatologic practice
Fernandez, A. P. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.012 · Cited by 61 · cited 1×
“Rationale: Available data from small studies suggest the risk of hemolysis is low among patients with G6PD deficiencies who receive hydroxychloroquine (88,89).”
BackgroundLecronier, M., Beurton, A., Burrel, S., Haudebourg, L., Déléris, R., Marec, J. L., Virolle, S., Nemlaghi, S., Bureau, C., Mora, P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03117-9 · Cited by 52
Management and Outcomes of Pneumonia Among Children With Complex Chronic Conditions
Leyenaar, J. K., Lagu, T. C., Shieh, M., Pekow, P. S., & Lindenauer, P. K. (2014) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000317 · Cited by 50
Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea
Choi, M. H., Ahn, H., Ryu, H. S., Kim, B.-J., Jang, J., Jung, M., Kim, J., & Jeong, S. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061959 · Cited by 48
Chloroquine Dosing Recommendations for Pediatric COVID‐19 Supported by Modeling and Simulation
Verscheijden, L. F. M., van der Zanden, T. M., van Bussel, L. P. M., de Hoop‐Sommen, M. A., Rüssel, F. G. M., Johnson, T. N., & de Wildt, S. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1864 · Cited by 42
Influenza in Children With Special Risk Medical Conditions: A Systematic Review and Meta-analysis
Tuckerman, J., Misan, S., Crawford, N. W., & Marshall, H. S. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002405 · Cited by 33 · cited 1×
“However, there is evidence to support more severe outcomes from other respiratory viral infections, such as influenza (36,37), parainfluenza (38), RSV (39–42), and non-COVID-19 coronaviruses (26,43), in children with chronic cardiac and pulmonary conditions.”
BackgroundThe Differential Clinical Impact of Human Coronavirus Species in Children With Cystic Fibrosis
Filho, L. V. R. F. D. S., Zerbinati, R. M., Tateno, A., Boas, L. V., de Almeida, M. B., Levi, J. E., Drexler, J. F., Drosten, C., & Pannuti, C. M. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis274 · Cited by 33 · cited 1×
“However, there is evidence to support more severe outcomes from other respiratory viral infections, such as influenza (36,37), parainfluenza (38), RSV (39–42), and non-COVID-19 coronaviruses (26,43), in children with chronic cardiac and pulmonary conditions.”
BackgroundNicastro, E., Giorgio, A. D., Zambelli, M. F., Ginammi, M., Bravi, M., Stroppa, P., Casotti, V., Palladino, R., Colledan, M., & D’Antiga, L. (2020) · Liver Transplantation · doi:10.1002/lt.25840 · Cited by 24
Cited by
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
Götzinger, F., Santiago-García, B., Noguera-Julián, A., Lanaspa, M., Lancella, L., Calò Carducci, F. I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., et al. (2020) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30177-2 · Cited by 1,219
SARS-COV-2 infection in children and newborns: a systematic review
Liguoro, I., Pilotto, C., Bonanni, M., Ferrari, M. E., Pusiol, A., Nocerino, A., Vidal, E., & Cogo, P. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-020-03684-7 · Cited by 552
Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E. A. B. A., Hadi, H. A., & Sultan, A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631139 · Cited by 177
“Such mechanisms include formation of immune complexes, viral mimicry, and host immune cell activation due to viral superantigen sequences (175) Treatment in children infected with SARS-CoV-2 consists mainly of supportive care, including oxygen and advanced respiratory support, hydration, and antipyretics (176, 177).”
Background
Metadata
- Authors
- Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A., Abzug, M. J., MacBrayne, C. E., Soma, V. L., Dulek, D. E., Vora, S. B., Waghmare, A., Wolf, J., Olivero, R., Grapentine, S., Wattier, R. L., Bio, L., Cross, S. J., Dillman, N. O., Downes, K. J., Timberlake, K., Young, J., Orscheln, R. C., Tamma, P. D., Schwenk, H. T., Zachariah, P., Aldrich, M., Goldman, D. L., Groves, H. E., Lamb, G. S., Tribble, A. C., Hersh, A. L., Thorell, E. A., Denison, M. R., Ratner, A. J., Newland, J. G., & Nakamura, M. M.
- Venue
- Journal of the Pediatric Infectious Diseases Society
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-22
- Volume
- 9
- Issue
- 6
- Pages
- 701-715
- ISSN
- 2048-7193 (ISSN-L)
- 2048-7207
- OpenAlex
- W3016479590
- Cited by
- 183
- References
- 145
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.